Evaluate the Safety and Effectiveness of Mannitol-combined Hyaluronan Supplement in the Treatment of Knee OA

N/ACompletedNCT05201040

SciVision Biotech Inc.132 enrolled

Overview

To evaluate the effectiveness and safety of JETKNEE Synovial Fluid Supplement for alleviating pain of knee osteoarthritis (OA).

The medical device is a bioabsorbable, extensible, crosslinked, 2% hyaluronic acid gel using micro-organism fermentation sourced hyaluronic acid as a major component and add mannitol is added which can inhibit the degradation of hyaluronate acid by free radicals to prolong the therapeutic effect. The medical device is injected into the articular cavity to protect joint tissue, increase joint lubricity, inhibit degradation of cartilage and promote the metabolism of cartilage by infiltrating degenerated cartilage. In addition, the medical device can penetrate the synovial tissue to inhibit inflammation and degradation. It also inhibits pain mediators in the synovium to achieve the pain inhibition. This study is to evaluate the effectiveness and safety of JETKNEE Synovial Fluid Supplement for alleviating pain of knee OA 6 months after single injection.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

132

Conditions

Knee Osteoarthritis Hyaluronic Acid

Interventions

JETKNEE Synovial Fluid SupplementDEVICE

2mL of JETKNEE Synovial Fluid Supplement

Normal salineDEVICE

2mL of normal saline

Eligibility

Sex: ALLMin age: 45 YearsMax age: 85 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Age 45 to 85 years of male or female. 2. Meet the ACR diagnostic criteria, the target knee is confirmed with OA by radiographic images and Kellgren \&Lawrence (K-L) score of 2 to 3； 3. Patients who still suffer from OA pain after receiving traditional non-drug therapy or general analgesic therapy within 6 months before the start of the study； 4. The VAS pain score of target knee must be at least 3 cm within 1 week before the screening and if the other side of knee has OA at the same time, the VAS pain score should be less than 3 cm； 5. Subject who has ability to understand the study purpose, comply with the study requirements, willing to stop all pain medications and physical therapy to the knees during the study and sign informed consent form (ICF). Exclusion Criteria: 1. The hip or ankle joints are diagnosed with OA, pain, or deformity； 2. K-L score of 4 by radiographic image evaluation； 3. The target knee has symptoms such as infection, redness, and swelling at the screening period and before treatment ； 4. The target knee has received hyaluronic acid treatment within 6 months before included in the study； 5. The target side has received lower limb surgery or knee operation with accompanied complications and significant mobility impairment within 6 months before the start of the study； 6. The target knee has received treatments such as steroid injection, arthrocentesis or arthroscopic surgery within 3 months before screening； 7. Patient with autoimmune disease (such as autoimmune collagenopathy, rheumatoid arthritis), malignant tumors, coagulation disorder, heart diseases, mental diseases…etc. which may cause higher risk to patients during participation in the study； 8. Receiving orthopedic-related treatments which may affect the evaluation of the study； 9. With history of hypersensitivity or allergy to hyaluronic acid or any component of the device; With history of hypersensitivity or allergy to Gram-positive bacteria or Streptococcus proteins； 10. Pregnant, planning pregnancy or in breastfeeding females during the study period； 11. Subject who cannot cooperate with the follow- ups； 12. Other circumstances which judged to be unsuitable for participating in the study by the investigator.

Locations (2)

Kaohsiung Municipal Siaogang Hospital

Kaohsiung City, Taiwan

Kaohsiung Veterans General Hospital

Kaohsiung City, Taiwan

Outcomes

Primary Outcomes

The pain score of Visual Analog Scale (VAS) of target knee at 6 months post-treatment.

The pain score of Visual Analog Scale (VAS) of target knee at 6 months post-treatment. Based on the patient described pain intensity as 0 to 10 score, a higher score indicates greater pain intensity.

Time frame: 6 months post-treatment

Secondary Outcomes

The pain score of VAS of target knee at baseline, 2 weeks, 1 month, and 3 months post-treatment

The pain score of VAS of target knee at baseline, 2 weeks, 1 month, and 3 months post-treatment. Based on the patient described pain intensity as 0 to 10 score, a higher score indicates greater pain intensity.

Time frame: baseline, 2 weeks, 1 month, and 3 months post-treatment

The average score of Western Ontario and McMaster Universities (WOMAC) in pain section of the target knee at baseline, 2 weeks, 1 month, 3 months and 6 months post-treatment

The average score of Western Ontario and McMaster Universities (WOMAC) in pain section of the target knee at baseline, 2 weeks, 1 month, 3 months and 6 months post-treatment The WOMAC measures five items for pain (score range 0-20).Higher scores indicate worse pain, stiffness, and functional limitations.

Time frame: baseline, 2 weeks, 1 month, 3 months and 6 months post-treatment

The average score of WOMAC in stiffness section of target knee at baseline, 2 weeks, 1 month, 3 months and 6 months post-treatment

The average score of WOMAC in stiffness section of target knee at baseline, 2 weeks, 1 month, 3 months and 6 months post-treatment. The WOMAC measures two for stiffness (score range 0-8).Higher scores indicate worse pain, stiffness, and functional limitations.

Time frame: baseline, 2 weeks, 1 month, 3 months and 6 months post-treatment

The average score of WOMAC in function section of target knee at baseline and 2 weeks, 1 month, 3 months and 6 months post-treatment

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.